News from omeros corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 08, 2018, 16:26 ET Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate...


Oct 26, 2017, 11:30 ET Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ: OMER) today announced further positive data from the company's ongoing Phase 2 study of OMS721 evaluating patients with...


Aug 11, 2016, 10:49 ET Omeros Announces Pricing of Public Offering of Common Stock

Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the...


Aug 10, 2016, 04:01 ET Omeros Announces Public Offering of Common Stock

Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the...


Jul 28, 2016, 09:27 ET Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with...


Nov 09, 2015, 04:10 ET Omeros Corporation Reports Third Quarter 2015 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


Nov 02, 2015, 07:00 ET Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


Oct 15, 2015, 07:00 ET Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®

Omeros Corporation (NASDAQ: OMER) today announced that it has launched OMIDRIAssure™, a comprehensive reimbursement services program to provide...


Sep 03, 2015, 09:15 ET Omeros Files Infringement Suits Against Par

Omeros Corporation (NASDAQ: OMER) today announced that it has filed patent infringement lawsuits against Par Pharmaceutical, Inc. and its subsidiary, ...


Aug 18, 2015, 07:00 ET Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of...


Aug 17, 2015, 07:00 ET Omeros Announces Plan to File Infringement Suit Against ANDA Filer

Omeros Corporation (NASDAQ: OMER) today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par ...


Jul 31, 2015, 04:50 ET Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


Jul 23, 2015, 07:00 ET FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to OMS721 for the...


Jun 17, 2015, 07:00 ET Rajiv Shah, M.D., Appointed to Omeros' Board of Directors

Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International...


Jun 16, 2015, 07:00 ET Omeros Announces Exclusive License Agreement for Omeros' Arthroscopic Product OMS103

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


May 22, 2015, 07:00 ET Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


May 11, 2015, 04:06 ET Omeros Corporation Reports First Quarter 2015 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


May 05, 2015, 07:00 ET Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and...


Apr 14, 2015, 07:00 ET European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721

Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product ...


Apr 09, 2015, 04:31 ET Omeros to Present at the 14th Annual Needham Healthcare Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Apr 02, 2015, 08:15 ET Omeros Corporation Announces the U.S. Commercial Launch of Omidria™

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Mar 16, 2015, 04:05 ET Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Mar 09, 2015, 06:03 ET Omeros Corporation to Announce Fourth Quarter and Full-Year 2014 Financial Results on March 16, 2015

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein...


Feb 19, 2015, 07:00 ET Omeros Corporation's Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use

Omeros Corporation (NASDAQ: OMER) today announced that it has completed dosing of the low-dose cohort of patients in its ongoing Phase 2 clinical...


Feb 03, 2015, 05:01 ET Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants

Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors on...